Sun Pharma introduces affordable drugs for epilepsy treatment
Brivaracetam is an anti-epileptic drug (AEDs) with fast onset of action and promising efficacy. Sun Pharma’s brand, Brevipil is the branded generic version of the innovator product, BRIVIACT® (Brivaracetam). Company to introduce Brevipil tablet 25 mg/50 mg/75 mg/100 mg, oral solution (10 mg/ml) and injectable (10 mg/ml).
Sun Pharmaceutical Now announced that the company will Present The comprehensive selection of Brivaracetam dosage forms at a reasonable price for epilepsy therapy in India. Brivaracetam is accepted by the Drugs Controller General of India (DCGI), as an adjunctive treatment in treating partial-onset seizures in patients 16 decades old and older with epilepsy.
Array of Brivaracetam in India in a competitive pricing that will improve patient accessibility. This item reaffirms our dedication towards improving epilepsy care by bringing numerous treatment alternatives to patients and healthcare professionals in India."
Brivaracetam belongs to the category of anti-epileptic drugs (AEDs) that have a distinctive or Different mechanism of action when compared with the present treatment choices. It's rapid onset of action and assuring efficacy. Long-term studies demonstrate that the answer obtained by means of Brivaracetam is continuing, together with favourable tolerability profile and compliance into the treatment.
While epilepsy is a common neurological disease, Due to the social stigma surrounding Epilepsy, cultural practices and inadequate comprehension of new treatment alternatives, direction of Epilepsy in India is still a challenge. It's projected that approximately 5.7 million to 6.4 Million people in India suffer with epilepsy.